Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 45% Improvement Relative Risk Case 31% c19early.org/p Seet et al. NCT04446104 Povidone-Iodine RCT Prophylaxis Is prophylaxis with povidone-iodine beneficial for COVID-19? RCT 1,354 patients in Singapore Trial compares with vitamin C, results vs. placebo may differ Fewer symptomatic cases (p=0.0022) and cases (p=0.012) Seet et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2021.04.035 Favors povidone-iodine Favors vitamin C
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial
Seet et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035, NCT04446104 (history)
Seet et al., Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035, NCT04446104
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower symptomatic cases, and lower confirmed cases of COVID-19 with all treatments (ivermectin, HCQ, PVP-I, and Zinc + vitamin C) compared to vitamin C.
Meta-analysis of vitamin C in 6 previous trials shows a benefit of 16%, so the actual benefit of ivermectin, HCQ, and PVP-I may be higher. Cluster RCT with 40 clusters.
There were no hospitalizations and no deaths. NCT04446104 (history).
risk of symptomatic case, 44.7% lower, RR 0.55, p = 0.002, treatment 42 of 735 (5.7%), control 64 of 619 (10.3%), NNT 22.
risk of case, 31.1% lower, RR 0.69, p = 0.01, treatment 338 of 735 (46.0%), control 433 of 619 (70.0%), NNT 4.2, adjusted per study, odds ratio converted to relative risk, model 6.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Seet et al., 14 Apr 2021, Cluster Randomized Controlled Trial, Singapore, peer-reviewed, 15 authors, this trial compares with another treatment - results may be better when compared to placebo, trial NCT04446104 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperPovidone-Iod..All
Abstract: International Journal of Infectious Diseases 106 (2021) 314–322 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial Raymond Chee Seong Seeta,b,* , Amy May Lin Queka,b , Delicia Shu Qin Ooic,d, Sharmila Senguptae , Satish Ramapatna Lakshminarasappaf , Chieh Yang Koog , Jimmy Bok Yan Soh , Boon Cher Gohi , Kwok Seng Lohj, Dale Fishera,e, Hock Luen Teoha,b , Jie Sunk , Alex R. Cookk , Paul Anantharajah Tambyaha,e, Mikael Hartmanh,k a Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore Division of Neurology, Department of Medicine, National University Hospital, Singapore Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore d Division of Pediatric Endocrinology, Khoo Teck Puat-National University Children’s Medical Institute, National University Hospital, Singapore e Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore f Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore g Department of Cardiology, National University Heart Centre, Singapore h Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore i Department of Hematology-Oncology, National University Cancer Institute, Singapore j Department of Otolaryngology-Head and Neck Surgery, National University Hospital, Singapore k Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore b c A R T I C L E I N F O A B S T R A C T Article history: Received 30 March 2021 Received in revised form 8 April 2021 Accepted 9 April 2021 Background: We examined whether existing licensed pharmacotherapies could reduce the spread of coronavirus disease 2019 (COVID-19). Methods: An open-label parallel randomized controlled trial was performed among healthy migrant workers quarantined in a large multi-storey dormitory in Singapore. Forty clusters (each defined as individual floors of the dormitory) were randomly assigned to receive a 42-day prophylaxis regimen of either oral hydroxychloroquine (400 mg once, followed by 200 mg/day), oral ivermectin (12 mg once), povidone-iodine throat spray (3 times/day, 270 mg/day), oral zinc (80 mg/day)/vitamin C (500 mg/day) combination, or oral vitamin C, 500 mg/day. The primary outcome was laboratory evidence of SARS-CoV2 infection as shown by either: (1) a positive serologic test for SARS-CoV-2 antibody on day 42, or (2) a positive PCR test for SARS-CoV-2 at any time between baseline and day 42. Results: A total of 3037 asymptomatic participants (mean age, 33.0 years; all men) who were seronegative to SARS-CoV-2 at baseline were included in the primary analysis. Follow-up was nearly complete (99.6%). Compared with vitamin C, significant absolute risk reductions (%, 98.75% confidence interval) were observed for oral hydroxychloroquine (21%, 2–42%) and povidone-iodine throat spray (24%, 7–39%). No statistically significant differences were observed with oral zinc/vitamin C combination (23%, –5 to +41%) and ivermectin (5%, –10 to +22%). Interruptions due to side effects were highest among participants who received zinc/vitamin C combination (6.9%), followed by vitamin..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit